that near-term calendar events include a planned September 12th
presentation at the 2014 Joint Americas and European Committees for Treatment and Research in Multiple Sclerosis Meeting (ACTRIMS-ECTRIMS) in Boston of additional Trimesta MS data, including important new findings in cognitive function, and a Company-sponsored IBS Investor Day planned for September 16th
in NYC which will include clinical presentations by Mark Pimentel, M.D., FRCP(C) of Cedars-Sinai Medical Center, the lead investigator of our 505(b)(2) compound, SYN-010 for constipation-predominant irritable bowel syndrome (C-IBS).
Three and Six Months Ended June 30, 2014 Financial ResultsGeneral and administrative expenses were $1.8 million and $2.9 million for the three and six months ended June 30, 2014, respectively, compared to $1.3 million and $2.4 million for the same periods in 2013. These increases of 44% and 23%, respectively, are primarily the result of supplemental compensation granted by the Board of Directors to executive officers and increased stock-based compensation expense. Non-cash charges related to stock-based compensation were $645,000 and $899,000 for the three and six months ended June 30, 2014, respectively, compared to $298,000 and $652,000 for the same periods in 2013.
Research and development expenses increased to $2.8 million and $5.6 million for the three and six months ended June 30, 2014, respectively, compared to $1.2 million and $2.3 million, for the same periods in 2013. These increases of 136% and 139%, respectively, are primarily the result of increased program costs associated with expanded research, development and manufacturing activities within our anti-infective pipeline, including the Company's C. diff, C-IBS and Pertussis programs. Non-cash charges related to stock-based compensation were $210,000 and $318,000 for the three and six months ended June 30, 2014, respectively, compared to $109,000 and $212,000 for the sa
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 Related biology technology :1
|SOURCE Synthetic Biologics, Inc.|
Copyright©2014 PR Newswire.
All rights reserved
. Synthetic Biologics Academic Collaborator to Present Novel Monoclonal Antibody Combination for Treatment of Whooping Cough (Pertussis) at 54th ICAAC2
. Synthetic Biologics to Report Second Quarter 2014 Financial Results3
. Synthetic Biologics on Track to Initiate Clinical Program for SYN-004 to Protect Against C. difficile4
. Global Synthetic Biology Market 2014-20185
. Synthetic Biologics to Present at the 7th Annual OneMedForum San Francisco 2014 Conference6
. Green Dot Develops Compostable Synthetic Leather Made with its Terratek® Flex Bioplastic7
. Synthetic Biologics Announces Exercise of Underwriters Over-Allotment Option8
. Synthetic Biologics Announces Proposed Public Offering of Common Stock9
. Global Geosynthetics Market 2012-201610
. Process holds promise for production of synthetic gasoline11
. Startup to Strengthen Synthetic Biology and Regenerative Medicine Industries with Cutting Edge Cell Products